RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Karam F. Soliman to Prostatic Neoplasms

This is a "connection" page, showing publications Karam F. Soliman has written about Prostatic Neoplasms.
Connection Strength

0.796
  1. Zarmouh NO, Messeha SS, Mateeva N, Gangapuram M, Flowers K, Eyunni SVK, Zhang W, Redda KK, Soliman KFA. The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells. Molecules. 2020 May 11; 25(9).
    View in: PubMed
    Score: 0.380
  2. Mochona B, Qi X, Euynni S, Sikazwi D, Mateeva N, Soliman KF. Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg Med Chem Lett. 2016 06 15; 26(12):2847-2851.
    View in: PubMed
    Score: 0.287
  3. Reams RR, Jones-Triche J, Chan OT, Hernandez BY, Soliman KF, Yates C. Immunohistological analysis of ABCD3 expression in Caucasian and African American prostate tumors. Biomed Res Int. 2015; 2015:132981.
    View in: PubMed
    Score: 0.066
  4. Green JE, Cooperwood JS, Taka E, Soliman KF, Goodman CB, Reams RR. Comparative proteomic analysis reveals growth inhibition by 3-N-alkyloxyestradiol derivative (SERM) in prostate cancer cells. Cancer Genomics Proteomics. 2014 Jul-Aug; 11(4):195-200.
    View in: PubMed
    Score: 0.063
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support